Xeris Biopharma Holdings Inc
XERS8.300USD
+0.630+8.21%
收盘 09/18, 16:00（美东）报价延迟15分钟
1.34B总市值
亏损市盈率 TTM
关于 Xeris Biopharma Holdings Inc 公司
Xeris Biopharma Holdings, Inc. 是一家生物制药公司，致力于通过开发和商业化一系列治疗产品来改善患者的生活。该公司有三种商业产品。Gvoke 是一种即用型液体稳定型胰高血糖素，用于治疗严重低血糖症。Recorlev 是一种皮质醇合成抑制剂，获准用于治疗无法进行手术或无法治愈的库欣综合征成年患者的内源性皮质醇增多症。Keveyis 是美国首个获批用于治疗高钾血症、低钾血症和原发性周期性麻痹 (PPP) 相关变体的疗法。该公司还拥有一系列开发项目，利用其专有的配方科学 XeriSol 和 XeriJect 推出新产品。其候选产品 XP-8121 旨在每周注射一次，小剂量，皮下注射，绕过胃肠道，可以避免许多治疗并发症。
公司简介
公司代码XERS
公司名称Xeris Biopharma Holdings Inc
上市日期Jun 21, 2018
CEOMr. John P. Shannon
员工数量394
证券类型Ordinary Share
年结日Jun 21
公司地址1375 West Fulton Street, Suite 1300
城市CHICAGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编60607
电话18444455704
网址https://www.xerispharma.com/
公司代码XERS
上市日期Jun 21, 2018
CEOMr. John P. Shannon
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
923.10K
-1.56%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
513.93K
+80.45%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
174.59K
+2.83%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
98.37K
-13.61%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
70.41K
-37.64%
Mr. Steven M. Pieper
Mr. Steven M. Pieper
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James Brady
Mr. James Brady
Independent Director
Independent Director
--
--
Mr. John P. Shannon
Mr. John P. Shannon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Allison Wey
Ms. Allison Wey
Senior Vice President - Investor Relations & Corporate Communications
Senior Vice President - Investor Relations & Corporate Communications
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
923.10K
-1.56%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
513.93K
+80.45%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
174.59K
+2.83%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
164.14K
+43.80%
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
98.37K
-13.61%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
70.41K
-37.64%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
业务USD
名称
营收
占比
Product revenue -Recorlev
25.53M
42.47%
Product revenue - Gvoke
20.84M
34.67%
Product revenue - Keveyis
11.43M
19.01%
Royalty, contract and other revenue
2.32M
3.85%
暂无数据
业务
地区
业务USD
名称
营收
占比
Product revenue -Recorlev
25.53M
42.47%
Product revenue - Gvoke
20.84M
34.67%
Product revenue - Keveyis
11.43M
19.01%
Royalty, contract and other revenue
2.32M
3.85%
股东统计
更新时间: 8月18日 周一
更新时间: 8月18日 周一
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.29%
The Vanguard Group, Inc.
6.08%
D. E. Shaw & Co., L.P.
2.38%
State Street Global Advisors (US)
2.34%
Geode Capital Management, L.L.C.
2.26%
其他
80.65%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.29%
The Vanguard Group, Inc.
6.08%
D. E. Shaw & Co., L.P.
2.38%
State Street Global Advisors (US)
2.34%
Geode Capital Management, L.L.C.
2.26%
其他
80.65%
股东类型
持股股东
占比
Investment Advisor
21.42%
Investment Advisor/Hedge Fund
16.56%
Hedge Fund
13.62%
Research Firm
4.34%
Individual Investor
4.04%
Pension Fund
0.43%
Sovereign Wealth Fund
0.35%
Bank and Trust
0.10%
Family Office
0.07%
其他
39.07%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
336
95.54M
59.64%
+13.83M
2025Q1
335
93.86M
58.93%
+12.36M
2024Q4
297
71.87M
48.21%
-8.26M
2024Q3
280
71.79M
48.23%
-5.89M
2024Q2
269
66.65M
44.99%
-10.81M
2024Q1
284
69.70M
49.68%
-4.28M
2023Q4
271
65.59M
47.45%
-7.22M
2023Q3
264
62.48M
45.27%
-15.54M
2023Q2
276
65.86M
49.56%
-15.25M
2023Q1
284
62.09M
46.86%
-20.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
9.59M
5.99%
-94.01K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
8.11M
5.06%
+210.58K
+2.67%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.05M
1.91%
+1.69M
+123.87%
Mar 31, 2025
State Street Global Advisors (US)
3.33M
2.08%
-16.62K
-0.50%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.41M
2.13%
+54.40K
+1.62%
Mar 31, 2025
Qube Research & Technologies Ltd
1.84M
1.15%
+1.38M
+301.34%
Mar 31, 2025
Millennium Management LLC
2.32M
1.45%
+369.42K
+18.96%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.15M
1.96%
+2.62M
+494.91%
Mar 31, 2025
Nuveen LLC
2.22M
1.39%
+324.06K
+17.07%
Mar 31, 2025
Two Sigma Investments, LP
1.82M
1.13%
+1.80M
+13115.57%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
SPDR S&P Pharmaceuticals ETF
2.1%
Virtus LifeSci Biotech Clinical Trials ETF
1.36%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.3%
Vanguard US Momentum Factor ETF
0.21%
iShares Micro-Cap ETF
0.18%
Federated Hermes MDT Small Cap Core ETF
0.17%
Principal U.S. Small-Cap ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
查看更多
SPDR S&P Pharmaceuticals ETF
占比2.1%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.36%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.3%
Vanguard US Momentum Factor ETF
占比0.21%
iShares Micro-Cap ETF
占比0.18%
Federated Hermes MDT Small Cap Core ETF
占比0.17%
Principal U.S. Small-Cap ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.08%
Invesco Nasdaq Biotechnology ETF
占比0.08%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
